I beg to move,
That this House
has considered community pharmacies.
It is a pleasure to serve with you in the Chair, Sir Mark. I thank the Backbench Business Committee for granting this debate, the purpose of which is threefold. The first is to thank community pharmacists for the great work that they have been carrying out in towns and cities for around 175 years. It was in 1849 that John Boot opened his first shop in Nottingham. More recently, the sector stepped up to the plate and was a key player in delivering the covid vaccination roll-out.
Secondly, I wish to acknowledge and support the Government for recognising in their delivery plan for recovering access to primary care, published in May, the key role that community pharmacists have been asked to play in the future of planning care.
Thirdly, and probably most urgently, there is a need to address the enormous pressures that community pharmacists currently face. If that is not done, the sector could cease to exist in large swathes of the country and will be in no fit state to perform the role for which it has successfully auditioned. There are clear comparisons to be drawn with the current state of NHS dentistry, and it is vital that action is taken to prevent a repeat of that particular nightmare.
A community pharmacy, previously known as the chemist’s in the UK and still known as the drugstore in the US, is a retail shop that provides pharmaceutical drugs as well as other personal products. There will be a qualified pharmacist available to issue medical prescriptions and to provide advice and guidance to customers on prescriptions and over-the-counter drugs, as well as on general health problems. Community pharmacies should be distinguished from the solely dispensing pharmacies located in medical practices and hospitals.
In my research for the debate I noted, as I have over the years, that in some places and at some times, relationships between GPs and community pharmacists can be fraught and strained. That needs to be addressed if the Government’s plans for improving access to primary care are to be successfully delivered.
In preparing for the debate I visited the Kirkley pharmacy at Kirkley Mill in Lowestoft and Boots in Beccles. I thank them both, as well as Tania Farrow and Kristina Boulton from Community Pharmacy Suffolk, for their advice, information and support.
Community pharmacies are made up of privately run businesses and corporate chains. It is important to emphasise that both those groups are going above and beyond what any business could reasonably be expected to do to keep their shops open. It is the framework within which they have to operate that is at fault, not them. The private businesses often work ridiculously long hours for no reward in the service of their local communities, and the corporate chains use retail sales to subsidise the pharmacy side of their operation. It is clear that if reform is not carried out urgently, the steady stream of closures will turn into a torrent.
While their number is falling by the day, there are approximately 10,800 community pharmacies in England. As I have mentioned, they do great work, and it was in recognition of that that the Government announced on
That will include expanded treatment options for seven common ailments, including earache, sore throats and urinary tract infections. Community pharmacists will also be able to assess patients and supply certain prescription-only medicines without a prescription from a GP. That vote of confidence is welcome, but there is a concern that, due to a real-terms reduction in funding, about which I shall go into more detail shortly, there is an element of robbing Peter to pay Paul.
We now need the detail of how pharmacy-first will work, so that integrated care boards such as the Norfolk and Waveney ICB can set about its implementation. There have been no further details since May, and I will be grateful if my hon. Friend the Minister can advise us when further information will be published.
An important part of the future of community pharmacy is for pharmacists to be independent prescribers. By 2026, newly qualified pharmacists will be able to start work having received the necessary training to become independent prescribers as part of their qualification. There is a need to ensure enough support to enable existing community pharmacists also to be trained as independent prescribers.
To become independent prescribers, pharmacists will need the support of a designated prescribing practitioner as part of their training. Sufficient investment is needed to ensure that that can happen, as designated prescribing practitioners will be required to support both those studying for their foundation pharmacist year in 2025-26 and the existing community pharmacists wanting to be trained as independent prescribers. Both will require 90 days in a prescribing environment.
Community pharmacists are under extreme pressure on multiple fronts—financial, workforce and regulatory, with many rules dating back to the 1930s. Medical supply instability is particularly acute. That puts operational pressures on pharmacists, imposes financial burdens on their businesses and creates worrying delays for their patients. Two of the biggest and interlinked challenges facing the sector, and indeed the whole of primary care, are access to services and the sustainability of the workforce. An increasing number of pharmacies are now providing core hours only, due to workforce challenges and financial sustainability. That means that fewer are offering services in the evening, at weekends and over bank holidays, and, in some cases, they are having to close much earlier during the day.
While the introduction of pharmacists working in general practice is to be welcomed, it has had the negative consequence of making it more difficult for community pharmacies to recruit pharmacists. A lack of access to pharmacy services cascades through other parts of the health system—to general practice, to the number of calls to NHS 111, to appointments to out-of-hours services and to visits to A&E.
Funding has been cut by 30% in real terms over the past seven years. As a result, so as to remain viable, community pharmacists are cutting back on the discretionary services that they provide. That ultimately leads to permanent closures—461 by Lloyds and 300 announced by Boots in June.
The 30% real-terms funding reduction, accompanied by inflationary pressures and workforce shortages, has driven up costs and has led to reduced hours and permanent closures. The £645 million for the new common conditions service announced in May is welcome, but it does not address the underfunding of existing core services. There is a need for a stable, long-term and sustainable funding commitment that can be delivered through a review of the community pharmacy contractual framework. This means not only additional funding, but alignment of care pathways and provision of incentives within primary care systems. The funding crisis has knock-on implications, including pharmacists being unable to spend as much time with patients as they would like, as well as the withdrawal of services such as free deliveries, particularly to care homes, and monitored dosage system boxes, which are important to many people.
To address these pressures and ensure that community pharmacies can realise their full potential, Community Pharmacy England has come forward with its own six-point plan. First, as I mentioned, pharmacy funding should be reformed to give pharmacies a long-term, economically sustainable funding agreement.
Secondly, a common conditions service should be developed and implemented so as to allow patients to have walk-in consultations for minor conditions. That would provide accessible care and ease pressure on general practice.
Thirdly, community pharmacies should look to build on other clinical service areas, such as vaccinations, women’s health and long-term conditions management for, say, asthma and diabetes, using independent prescribing rights. In this way, pharmacy can do a great deal in key NHS priority areas and will help to get the health service back on a sustainable footing.
Fourthly, the medicines market must be reformed so as to get out of the situation we are now in, where pharmacies are dispensing some medicines at a loss and patients are facing long delays for medicines.
Fifthly, regulatory burdens should be reviewed and where necessary removed, so as to make running community pharmacies easier and to limit the increasing cost of service provision.
Sixthly and finally, a long-term plan for the community pharmacy workforce should be produced to ensure that pharmacies can keep their doors open and to enable them to retain pharmacists in local pharmacies.
In many respects, this debate is a trailer for the main attraction next Tuesday, when Community Pharmacy England launches its vision for community pharmacy, as prepared by the King’s Fund and the Nuffield Trust. In the delivery plan for recovering access to primary care, the Government undertook to continue to engage with the sector, with specific reference to the piece of work that is being published next Tuesday. I urge the Government to adhere to that commitment, which is vital not only to rebuilding primary care but to giving community pharmacies a sustainable and viable future, thereby ensuring that after 170 years they can remain part and parcel of the fabric of our towns and cities.
It is always a pleasure to take part in a debate when you are in the Chair, Sir Mark. I congratulate Peter Aldous on the timeliness of this debate and on the typically thoughtful way in which he presented his case. If I repeat some of his arguments, it is not that I am gratuitously copying what he said; the themes need to be emphasised, and I will try my best to do so.
At Prime Minister’s questions on
“a wholehearted champion of and believer in the role that community pharmacies can play.”—[Official Report,
Vol. 731, c. 732.]
Two weeks later, on
“the incredible role that pharmacists played during the pandemic—their capacity to innovate and deliver for the communities that they served, freeing up GP appointments in doing so”.—[Official Report,
Vol. 732, c. 219.]
As part of that approach, the Secretary of State committed to investing up to £650 million over the next two years, so that pharmacists can supply prescription-only medicine for common conditions such as ear pain, a urinary tract infection or a sore throat, without requiring a prescription from a GP. In the time available, I want to explore how that policy is developing and how the resources that the Government have earmarked meet the requirements for pharmacies to deliver such a service. I should add that the Secretary of State’s list could easily be added to, and I hope it will be.
“We are currently negotiating on how this funding commitment will be delivered to ensure that community pharmacies can meet patient needs and we welcome the confidence and additional investment in community pharmacy...Until those negotiations are complete, we do not know the extent to which this additional investment will help community pharmacies with these current pressures, but we do know that it will not address all of the pressures as outlined later in this briefing.”
Pharmacists refer to a funding black hole; I do not think the hon. Member for Waveney used that term, but he did use the figures involved. They point out that the recent announcement of funding is welcome but represents
“new money for new workers”.
They go on to say that there is currently an annual funding shortfall of at least £67,000 per pharmacy. Consequently, there is insufficient money in the system to deliver the services that they are already contracted for, let alone to take on new ones.
The CCA also draws attention to the trend between 2015 and 2022, which saw the permanent closure of 720 pharmacies. On a recent visit to Asda in Huyton in my constituency, I saw the consequences at first hand. The Asda pharmacy, which by the way is admirable, is having to fill the gap created by the loss of other smaller, independent local pharmacies, and the pressure on the dispensers while I was there was relentless. There was not a minute to pause for thought or have a conversation with people coming to pick up their prescriptions, because they were so busy.
Of the pharmacies that closed, 40% were in the 20% most deprived areas of England. That is worrying for me as the MP for Knowsley, which is one of the areas of greatest deprivation. One way in which high levels of deprivation are reflected is in the number of people in Knowsley living with long-term health conditions, which account for 70% of the total healthcare spend, 64% of hospital out-patient appointments and 50% of GP appointments. If community pharmacies could be deployed to deal with some of those cases where appropriate, that could help immensely in easing the burden on the NHS services that currently have to deal with them.
As the Minister will be aware, and as the hon. Member for Waveney referred to, there is a workforce crisis in community pharmacies in England. There is estimated to be a shortfall of 31,000 pharmacists. The Asda community pharmacy I visited had vacancies, one of which was for a pharmacist; I think they had been trying for a year, unsuccessfully, to fill the position.
I also want to raise the issue of medical supply chains. The current level of allowable margin is £800 million; it was first agreed in 2014 and has not been reviewed since. That amounts to an annual reduction in the margin available. In practice, all pharmacies are faced with diminishing resources for the purchase of medical supplies. On
This problem will lead to more local pharmacy closures and reduced capacity to serve the new pharmacy-first policy. As CPE puts it, reforms are needed
“to the medicines market to avoid the situation we are now in, where pharmacies are dispensing some medicines at a loss and patients are facing delays for medicines.”
Pharmacy2U, which is a delivery service, has pointed out that stakeholders now have to deal with the issue. It notes the difficulty with the interoperability of IT systems and points out that
“there is significant variation in the systems used by GPs, and pharmacy services are often unable to easily access patient records, heavily restricting their ability to support patients with their medicines. Ensuring that pharmacists have swift access to this data is vital in empowering pharmacies to play a central role in a reformed and improved primary care system.”
It suggests that
“HSC and NHSE should consult with system-wide stakeholders to ensure all pharmacists are enabled to access and, where appropriate, update patient records in line with data privacy rights, ensuring that GPs and pharmacies have a complete picture of the patient they are caring for.”
I will make one final point before asking some questions. I wrote to the Secretary of State on
I will conclude with a few questions. First, how do the Government propose to address the funding black hole that I have referred to? Secondly, what is the Government’s strategy for halting the alarming number of pharmacy closures? Thirdly, how do the Government intend to address the workforce shortages? Fourthly, will the Minister agree to consult stakeholders on how to deal with the issue of interoperability of IT systems? Finally, how does the Minister propose to enable all pharmacies, including independent pharmacies, to fund the gap between the cost of acquiring medicines and the resources available?
It is nice to see you in the Chair, Sir Mark. Well done to my hon. Friend Peter Aldous, my dear friend with whom I entered Parliament in 2010: as always, he has set out the issues beautifully, with the forensic ability for which he is known. The people of Waveney are very lucky to have him, as is this House. It was my hon. Friend who inspired me to speak in this debate: he collared me in the corridor, as he often does. I am only too pleased to do so, both as MP for Winchester and Chandler’s Ford and as Chair of the Health and Social Care Committee.
When I was pharmacy Minister, I spent many happy hours where the Minister is sitting today, answering debates on the subject. We have moved on a lot, and I give credit to the Minister, the Secretary of State and this Prime Minister of all Prime Ministers—if they had not understood community pharmacy, we were never going to get there. All credit to them for the investment and the work that has gone on. As somebody once said, “Much done, more to do.”
My fellow Committee members, one of whom is here today, and I are all too aware of the challenges facing community pharmacies in all our constituencies. Nevertheless, there is great cause to be positive. In my opinion, pharmacies have huge untapped potential to transform the way patients access and receive healthcare services, and to support the building of a preventive healthcare approach, which the Minister knows I am passionate about and which I suggest is central to the future sustainability of the NHS itself.
Earlier this year, the Select Committee launched an inquiry into pharmacy. It will look broadly at pharmacy services including hospital pharmacy, which is often overlooked but is very important, but community pharmacy will form the largest part of it. The terms of reference include specific questions about funding, which my hon. Friend Sir George Howarth both mentioned; the commissioning arrangements for community pharmacy, which I know we will come on to; the locations of community pharmacies; and, of course, achieving the ambitions of Pharmacy First in the primary care recovery plan. I trialled Pharmacy First in the north-east when I was pharmacy Minister; I am a great believer in it, so it is great to see how the Minister has taken it forward.
A key question that our inquiry seeks to answer is, “What does the future of pharmacy look like, and how can the Government ensure that it is realised?” We will be very forward-looking, considering how the challenges of today can be addressed to ensure that the potential is realised. However, we will also look at the services that community pharmacies are already offering or are set to offer through the pharmacy-first approach. Crucially, we will also consider the areas in which there is a chance to go further.
Community pharmacists are highly trained clinical professionals. They are not retailers; they are clinical professionals. They want to do more, they can do more and we should trust them to do more. We will also consider some of the innovations in the sector—for example, how automation and hub-and-spoke arrangements, which we have not talked about much today, will come in and help. We will also look at the workforce challenges, which we have heard about, including issues around the retention of pharmacists in the community pharmacy sector and around training.
The inquiry will be wide ranging. We are looking forward to getting started with oral evidence, hopefully in November. There is no shortage of enthusiastic people in the community pharmacy sector who are willing to share their experiences with us. We are incredibly grateful to all those organisations and individuals who sent in their written evidence, and we hope to continue seeing that positive engagement from the sector when we start the oral evidence sessions.
The Committee has the benefit of drawing upon the work of our expert panel, which is chaired by Professor Dame Jane Dacre, whom the Minister will know. The panel, set up by my predecessor, now the Chancellor of the Exchequer, evaluates the Government’s progress on meeting their commitments on an area that I ask it to look at. It delivers a Care Quality Commission-style rating as to where we are, which can range from “outstanding” to “inadequate”. I asked the panel to look at the pharmacy sector, based on its own members’ expertise and research and submissions by stakeholders, as well as some roundtable events with patients, people in receipt of social care, and pharmacy professionals.
The panel recently published a report on its evaluation of Government commitments in the pharmacy sector. It was assisted by several pharmacy professionals and leaders who steered its decision on which commitments to evaluate. Community pharmacies were an obvious area to focus on. The panel looked at two specific community pharmacy-related commitments, rating the position on both as “requires improvement”. I take a glass half-full perspective. There are good things in the report; I know that the Minister will look carefully at it. The first commitment was to maintain the pharmacy access scheme, which aims to protect access to local, physical NHS pharmaceutical services in areas where there are fewer pharmacies. The chemist may be the only shop in town—that is often the case in coastal communities.
The second commitment was to review the community pharmacy funding model and the balance between the spend on dispensing and new services within the community pharmacy contractual framework, which is negotiated between Community Pharmacy England—formally the Pharmaceutical Services Negotiating Committee—the Government and NHS England. The panel concluded that community pharmacies are struggling to meet increased demand. It is a good thing that demand is increasing, because it means that people are increasingly turning to the chemist, but they are struggling to meet that demand, to deliver services, and even to remain open with the current funding model, which was set in 2019 for five years and has not been reviewed significantly during that time.
As my hon. Friend the Member for Waveney suggested, pharmacies are also struggling as their staff are encouraged to take up roles in primary care, funded by the additional roles reimbursement scheme. The right hon. Member for Knowsley touched on the fact that IT systems can make it difficult for patient information to be shared between community pharmacies, hospitals and general practices. Taken together, those challenges can negatively impact community pharmacies’ ability to deliver services and support other parts of the health and care system.
The National Pharmacy Association does great work in this space and has been in touch with us. It commissioned an EY report, which found that almost three quarters of pharmacies in England face a risk of closure if a serious funding shortfall is not addressed, with 72% of them forecast to be loss-making within the next four years. The Minister will be aware of that report. It is sober reading, but it would be wrong to overlook it. It is a serious piece of work.
Going back to the expert panel, members also raised concerns about the lack of data collected on the performance of schemes designed to improve community pharmacy services, especially whether they were delivering the positive outcomes that we want for patients and people in receipt of social care. There is a lot for the Government to consider in the panel’s report. We still await their response, which, I hasten to add, has not timed out yet. We look forward to that.
I want to touch on a couple of other points. First, I co-chair the all-party parliamentary group on HIV and AIDS. We are calling for the HIV prevention pill, PrEP—pre-exposure prophylaxis—to be available through community pharmacies, with clear financial accountability for its provision. I think that would be a game changer for HIV prevention. It would be a critical part of ending new cases of HIV by 2030, urged by the HIV Commission, which I commissioned as the Minister and, after leaving Government, became a commissioner on, along with the shadow Secretary of State, Wes Streeting. The Opposition Front Benchers have signed up to that 2030 ambition, and the Government have committed to it too.
Community pharmacies are well placed to prescribe PrEP. They carry out medicine use reviews for patients, and I think that they would be well placed to counsel on PrEP and to manage the prescriptions alongside other medications, because it is critical that medicines are prescribed in conjunction with each other. Community pharmacies are well connected to other parts of the health service, where integrated care boards have ensured that the IT is right and that the relationships are right. Furthermore, services provided by pharmacies act as a bridge between secondary and primary care, so that would complement sexual health prevention and treatment services and the advice that goes on. Will the Minister, in his summing up, touch on what progress has been made towards the commitment to make PrEP available beyond sexual health services and when it will be available in community pharmacies?
On the supply side, we have talked a lot about the bricks and mortar and the workforce, but the medicines supply chain, also mentioned by both previous speakers, is in need of serious love from Ministers. Pharmacies often have no idea of the prices being charged by wholesalers for some key generics, so they have no idea what is short, while pricing of products is often much higher compared with other European countries; consequently, margins in community pharmacies are often being eroded by uncertainty in the supply chain. I urge the Government to look at a robust system to plan for future pandemics and address shortages of key pharmaceuticals, because that undermines the sector and some of its great work.
There are so many things we could talk about, such as the ill-health prevention inquiry by the Select Committee, where I see pharmacies playing a key role. Much has been achieved. When I walked into the Department, I asked the special advisers what should be on my worry list, and they said: “General practice, Minister.” Some things never change. However, I passionately believe that community pharmacies are part of primary care, or pre-primary care as I used to call it. When I talked to parts of the primary care sector as the Minister, they would say to me: “We want to do more. We can do more. We are trained clinical professionals who can be trusted to do more.” The Government have picked up the mantle of that through the reform of, and new investment in, the contract, with the Prime Minister putting his personal authority behind the sector.
There is therefore much to be proud of, but we have to be careful that we do not end up losing community pharmacies. If we lose them, once they have gone, they will not come back, and we will have a supply-side problem in the bricks and mortar, as well in some of the pharmaceuticals. I thank my hon. Friend the Member for Waveney for securing the debate—it is, as always, an excellent subject for the House to discuss—and thank you, Sir Mark, for calling me to speak.
It is a pleasure to serve under your chairmanship, Sir Mark.
I congratulate Peter Aldous on securing this important and timely debate. I say “timely”, because only last week I delivered a petition to Parliament on this very subject, with the support of hundreds of people in my constituency. I know the strength of feeling across Bradford South on this issue, and about the value people place on community pharmacies.
I speak in defence of funding for our community pharmacies’ core services, which have been cut in real terms in recent years. Furthermore, I reiterate the point made by my right hon. Friend Sir George Howarth that our remarks cover many of the same areas, because they are so important to our constituents.
Community pharmacies are essential pillars of our national health service. The Government’s independent review described the open secret that community pharmacies are an “under-utilised resource”. As many of my constituents have put it to me, they are far more than just a place to get medicines; they are part of the very fabric of our local community. They are valued. Community pharmacies offer vital, immediate face-to-face services, often supplementing GP services, though without some of the vital resources that they need and deserve. When this country faced the covid pandemic, community pharmacies were there for us all. They stepped up bravely, maintained access to vital medicines, provided healthcare advice and delivered a record number of vaccinations. Now is the time to both thank them and show them that we value our community pharmacies, and not to abandon them to what one of my local chemists described to me as “funding starvation”.
After 13 years of under-investment, the NHS is at breaking point, and pharmacies are suffering from lack of funding. More than 700 pharmacies closed permanently between 2015 and 2022, and over 40% of these closures took place in the 20% most deprived areas of the country—cuts, yet again, where services are most acutely needed. In the words of one of my Bradford South chemists, James Currie, this
“is yet another clear demonstration by this Government of their detachment from the realities and needs of the communities we serve.”
Pressures on pharmacies have been worsened by a workforce crisis, with an estimated shortfall of 3,000 community pharmacists in England. I will be grateful if the Minister clarifies how the additional roles reimbursement scheme will be “carefully managed” to ensure that we are able to recruit, train and, importantly, retain the pharmacists we so desperately need. We know that pharmacy funding was cut by 30% in real terms between 2015 and the beginning of this year. More and more work is now being piled on our community pharmacies, without adequate additional resources—a familiar pattern for our public services in the UK today. That has created a serious funding black hole, with an annual shortfall in England of an estimated £67,000 per pharmacy.
The pattern of reckless under-investment is simply not sustainable, so it was welcome news that NHS England’s delivery plan for recovering access to primary care said that further funds will be devoted to community pharmacies to expand their services. The new Pharmacy First common conditions service is a strong step towards easing pressures on GP services, but pharmacies are already overstretched and support for their delivery of core services is still inadequate. I ask the Minister to clarify the extent to which the additional investment will be earmarked for addressing existing pressures on core services.
In preparing for the debate, I found it useful to look back at the Government’s independent review of community pharmacies, published seven years ago. In the report, it was made clear that community pharmacies would be urgently required to help deal with
“immediate financial and operational pressures” in the wider health service. Seven years later, however, the NHS is still struggling to deal with an historic backlog. I am sure that all right hon. and hon. Members present will recognise that community pharmacies are part of the wider solution to this very serious problem.
It is high time that we broke the cycle of crisis after crisis, followed by rushed solutions. Fair funding for community pharmacies will not only help support the local communities they serve, but strengthen the wider national health service and enable a vital and much-needed “prevention first” approach.
It is a pleasure to speak in today’s debate with you as Chair, Sir Mark. I thank my hon. Friend Peter Aldous for securing this important debate on community pharmacies, which are a crucial part of our healthcare ecosystem. I also thank him for his thorough explanation of the current state of community pharmacies and their needs.
I am often reminded that when we feel unwell or something has gone a bit wrong, our first point of call is often to walk into a pharmacy to get advice, support and medicine. Somebody there can put one’s mind at ease. Those who are vulnerable or elderly can also get their medicines delivered to them, which adds to the wellbeing of the local community. However, despite community pharmacies’ immense importance, they face huge challenges. Increasing demands and ongoing pressures are threatening their sustainability. Tatton currently has a healthy number of local pharmacies—18— supporting nearly 70,000 residents. However, pharmacies are disappearing across the country—and in Tatton, too. Government figures show a decrease of 222 between December 2022 and June 2023. The reasons for those closures include inadequate funding, rising operational costs and difficulty in recruiting and retaining community pharmacists.
Tatton community pharmacist Lee Williams, along with his wife and fellow pharmacist Caroline, were two of the first constituents I met at their pharmacy in Knutsford when I became the MP for Tatton back in 2017. They have since had to close their pharmacy. Lee explained to me that, despite it being a busy community pharmacy and having a good reputation—I can vouch for that, as I went there, too—they had very much a hand-to-mouth existence as funding fell and things such as rent, utilities and wages increased, squeezing their profit margin to the point where their business became unviable and the only thing they could do to safeguard their 12 years of tireless work was to sell it. It was a sad day for them, because their dream was for the two of them, married, running this community pharmacy and supporting the local community, but it had become abundantly clear to them for some time that the only way for such pharmacies to exist was to find efficiencies through having multiple branches. But now, even the large multiple retailers such as Lloyds and Rowlands have had to sell off their community stores as they move to remote delivery and go online in an attempt to become profitable. Even they cannot make community pharmacies work.
Adding to the problem of underfunding is, as we have heard, a shortage of medicines, which often results in community pharmacists dispensing medicines at a loss. Even when the NHS decides to increase the price it is willing to reimburse pharmacists for those medicines, it often comes after weeks of pharmacists gambling on what price they will have to pay, which creates huge uncertainty for them and their businesses. Ironically, it is the very low prices that the NHS is willing to pay that drive the shortages. If a manufacturer can sell those medicines for a higher price in other countries, it will prioritise those markets over our own. Community pharmacists find that their staff, in their role as pharmacists, are spending a lot of their time trying to find stock, on top of their crippling workload.
Community pharmacy is therefore at a low—the pharmacists would say an all-time low—which corresponds to much of the results of Community Pharmacy England’s 2023 pressures survey. It found that 92% of pharmacies are dealing with medicine supply issues daily, which was an increase from 67% in 2022; 97% of pharmacy owners reported significant increases in wholesaler and medicine supply issues; 81% of pharmacy staff said they were “struggling to cope” with the significant increase in workload; and 84% had experienced aggression from patients due to medicine supply issues. Worse—if things could be worse—pharmacists face more abuse from the public because of drug shortages.
To keep our community pharmacies afloat, Lee Williams advocates a complete overhaul of how community pharmacies are viewed and remunerated. I therefore welcome the Government’s announcement of £645 million of new funding for Pharmacy First. The Government realise that things need to be done. Much has been done but more needs to be done, and they need to pursue that as well as they can. We can say that with our Prime Minister as an advocate. However, in the light of the first-hand experience of my constituents that I have just shared and those survey results, how is the Minister ensuring the security and consistency of supply of medicines? How will the Government compensate pharmacies for the extra costs of offering additional services such as annual health checks, which require more skilled staff? I appreciate the difficulty of finding more funding for the sector, but I know that the Government will be looking to do that, so will the Minister explain how? Local pharmacies want to be at the heart of the health sector and take more of the workload off the NHS, but in order to do that they need to be adequately recompensed. They provide a vital service, and I know that they want to do even more.
It is a pleasure to serve under your chairmanship, Sir Mark. I thank Peter Aldous for securing this important debate and highlighting the challenges faced by the pharmacy sector. He spoke with great knowledge about many of the challenges around funding, and the opportunities for the pharmacy sector to address some of the primary care challenges faced by the NHS. I highlight the points made by the Chair of the Health and Social Care Committee, Steve Brine, who has been very supportive of the pharmacy sector and has played a key role in pushing for the Committee to publish a report on the role of the sector and the challenges it faces.
I declare an interest as a registered pharmacist, the chair of the all-party parliamentary pharmacy group, and a member of the Health and Social Care Committee. I apologise to Members present, as I might end up repeating some of the points that have already been made, but I will try my best not to focus on them.
The first challenge I will highlight is the massive issue of the medicine supply chain. Every time I speak to pharmacy owners and pharmacists they raise the impact that uncertainty has on their profit margins. I recently started engaging with the pharmaceutical sector to understand the issues. There are issues around medicine distribution in this country, and there are middlemen supply chain distributors who keep hold of medicines and who are sometimes involved in driving up the prices, but we also have challenges around the manufacturing of generics, which account for about 80% of medicines used by the NHS.
About 2.2 million generic drugs are prescribed every single day in this country and used by the NHS. Despite that, it seems there were some oversights in this area when we negotiated our exit from the EU. Currently, legislation allows EU generics to be recognised in the UK but does not allow the EU to recognise UK generics. That means that British manufacturers are unable to submit their marketing authorisation applications easily within the EU. Therefore, they have no incentive to produce these medicines, or increase their manufacturing of these medicines, in the UK. It also means that they are unable to compete with their European competitors.
A great example of what is happening is that the EU has started investing about £20 billion in the manufacturing of generics since we left. So far, the UK, according to figures that I have seen recently, has invested nothing. Essentially, our UK manufacturers are being left at a competitive disadvantage. Aside from that, the Medicines and Healthcare products Regulatory Agency is facing significant challenges. It has lost a large amount of its workforce and is currently unable to process the regulatory applications coming through its doors—again, making it difficult for generic drugs to enter the UK. Essentially, there are regulatory difficulties and there seem to be limited financial incentives.
Secondly, I want to address the challenges of finance, which have been a massive issue facing the pharmacy sector. The sector has not been adequately funded in line with inflation for a very long time. That has led to many high street pharmacies closing down. In my constituency, Boots in Jardine Crescent had to close down because it was not financially viable for the business to continue. That has had a significant impact in an area of great deprivation and high health inequality.
Despite the challenges that community pharmacies face, there are also wonderful opportunities, which I have to admit the Government have started to recognise. I welcome their more than £600 million investment in the Pharmacy First programme, but there is a long way to go to fully take advantage of the potential that community pharmacies can offer.
Community pharmacies play an important role because they are the first point of call for patients, but they can play a bigger role in healthcare. Not only can they deliver the Pharmacy First scheme—I hope that will be rolled out and that the Government will add more clinical conditions to the list—but they can play an important role in other primary care services, such as vaccination, sexual health and the management of conditions such as cardiovascular disease.
I have always found it weird how a patient will come up to me in the pharmacy and say, “I have high blood pressure. I’m a bit concerned.” I say, “Sit down. Let’s check your blood pressure” and then I have to message the doctor to let them know. Then I will tell the patient to go to their GP to get a medication. In reality, that could have started and ended in a community pharmacy. That is something that hospital pharmacists easily do, and we regularly do it, so I encourage the Minister to look into the wider roles that community pharmacists can play in supporting GPs and primary care and in reducing some of the challenges it currently faces.
Many Members have spoken about the workforce crisis. To be able to fully take advantage of the potential of community pharmacy, we have to acknowledge the fact that, like many other healthcare professions in this country, pharmacies face a significant workforce crisis. We do not have enough pharmacists, and we are struggling to recruit and train more and to retain the community pharmacists we have.
Again, I welcome the Government’s workforce plan, but unfortunately it lacks the finer details of how community pharmacy will be supported in the long term. An integrated and funded workforce plan for pharmacy is needed if we are to enable pharmacies to support the community as well as the rest of the NHS. A larger number of designated prescribing practitioners is needed if community pharmacies are to assist with the provision of primary care. A clear pathway to ensure that that happens is important.
I know that the Government aim to ensure that we get as many prescribers as possible by 2026, and that is something I welcome. I am really happy that pharmacists are able to graduate with the ability to prescribe. However, there are many pharmacists in the workforce for whom there is no clear plan as to how they can become prescribers by 2026. I have spoken to many different pharmacy schools and they do not know how that is going to happen.
As the hon. Member for Waveney has explained, the process for getting sign-off is not easy. People have to ensure that they have found the right healthcare professional to shadow, as well as take time off work to do all the documentation and paperwork that is needed. Changes therefore need to happen, and further funding needs to be made available to incentivise healthcare professionals to take on more pharmacists and to mentor them and train them to become prescribers.
I also want to address areas that have not been mentioned in the debate so far. The first is technology, which has played a significant and positive role in the provision of the healthcare system. Since covid, technology has played an important role in allowing patients to have easy access to healthcare and allowing them to feel empowered. That is the reason we have seen an increase in the number of online pharmacies that are available, which has been quite positive.
However, I have some concerns. Figures recently published by the General Pharmaceutical Council, which is responsible for inspecting community pharmacies and online pharmacies, show that at least one in five of the online retailers it inspected in the past year did not meet at least one standard. If that was a community pharmacy, the store would be put on a clear supervision pathway to ensure that patients’ health was not put at risk. I would like to see the same happen to online pharmacies to ensure that they are better regulated as they continue to provide better access to medicines for patients.
I welcome the fact that the Government are looking at the supervision rules, which are outdated and were created at a time when we were making medicines in pharmacies and playing around with different active pharmaceutical ingredients. Pharmacy has changed since then, and the information available and the regulation around drug manufacturing has significantly improved. I welcome the consultation that is being carried out, and I encourage as many pharmacists as possible to give their feedback and engage with the consultation.
Lastly, I want to turn to the regulation of non-clinical managers. Community pharmacies either have a pharmacist as a manager or have non-clinical managers leading them. In the light of the Lucy Letby case, which highlighted the important role that non-clinical managers play, it is important that community pharmacists are also considered. Any new regulatory framework for unregulated management and leaders in healthcare should apply to not only those working in the NHS but those who have direct involvement in the provision of healthcare in our communities, such as community pharmacy.
Before I end, I would like to ask the Minister a few questions, which I hope he can answer today or respond to in a letter. Has any consideration been given to the generic industry, which, as I said earlier, accounts for a large amount of medicine supplies within the NHS? Can he direct me to the Minister who is responsible for drug manufacturing in this country, the changes in EU legislation and how we can bring about positive changes for our generic manufacturing industry? Do the Government have any plans to prevent future medicine shortages? I am already hearing pharmacies expressing concerns about the fact that winter is coming and they are expecting to have further shortages.
Are there any updates on the mutual recognition of medicines within the EU, and are any negotiations happening? Can the Minister provide an update on the prescribing scheme for healthcare professionals and whether any steps have been taken to address the issues I have raised? On funding, it would be helpful for many pharmacists to know whether there are any plans to help address some of the financial challenges they face. Lastly, as the chair of the all-party parliamentary pharmacy group, I wonder whether the Minister could spare some time to come and speak to key stakeholders in the sector, who would love to meet him and share some of their experiences.
It is a pleasure to serve under your chairmanship, Sir Mark. I thank Peter Aldous for securing this important debate, and I congratulate him and Members on both sides of the Chamber on putting forward a compelling argument for supporting our community pharmacy sector and increasing its role in the provision of localised community healthcare. I thank my right hon. Friend Sir George Howarth; Steve Brine, who chairs the Health and Social Care Committee and who made some excellent contributions; my hon. Friend Judith Cummins, who has been campaigning on this issue; Esther McVey; and my hon. Friend Taiwo Owatemi, who is a pharmacist and who shared her first-hand experience of some of the challenges. We have heard some great contributions in this debate.
It is a great pleasure to take on this important portfolio covering primary care and public health. In this year—the NHS’s 75th—its founding mission, to deliver care to everyone who needs it, when they need it, free at the point of use, is clearly under threat. Thirteen years of Conservative Government have left the NHS flat on its back, and the rightful expectation of my constituents and people across the country of an NHS with time to care for them when they need it is being trampled. We see longer waiting times, a postcode lottery in care and, shamefully, for the first time in decades, healthy life expectancy falling in many regions across the United Kingdom, including the west midlands, which I represent. That is one of the starkest indicators of how this Government, far from levelling up the country, have let it down.
The NHS is Britain’s greatest institution and my party’s proudest achievement, and nothing gives me fire in my belly like the prospect of what a Labour Government will do to fix it. Community pharmacy is a huge part of that, relieving pressure on overstretched GPs and delivering first-class care and advice to patients. As many hon. Members have highlighted during the debate, it is high time we realised the potential of pharmacies; as with the vaccine roll-out during the pandemic, they have proven time and again that there is so much more they can deliver as part of the primary care mix.
Pharmacists are the third biggest profession in the NHS, with around 13,000 community pharmacists across the UK, and together they prescribe more than 1 billion medicines a year. Not only are pharmacists medicine experts within the NHS, but colleagues have acknowledged their wider skills and knowledge, which are under-utilised. It is estimated that pharmacists give around 58 million informal consultations to walk-in patients a year, saving 20 million GP appointments. We also know that drug-related problems, often resulting from poor medicine management, cause around 15% of hospital admissions and cost the NHS hundreds of pounds a night, so pharmacies have an enormous contribution to make to the wider system.
Chemists do far more than just dispense repeat prescriptions and sell shampoo. They provide a range of clinical services in prescribing for common ailments and have a key role to play in public health and preventive services. There are great examples of innovative public health work that pharmacists are doing, such as in Bradford, where the “Wise Up to Cancer” initiative promoted health literacy among south Asian women, or the Jaunty Springs Health Centre in Sheffield, where a shared care agreement between the pharmacy and GP surgery meant that a majority of health interventions could be delivered in the pharmacy consultation room, freeing up the GP and cutting waiting times.
There is good practice in pockets across the country that we should be building on. I know that Ministers have belatedly acknowledged that, and there has been some expansion of the clinical services that pharmacies offer in recent years. However, a few sticking-plaster proposals really miss the opportunities that are there. Will the Minister update us on how negotiations with the sector over the Pharmacy First launch are progressing, and can he promise that it will be operational in time for the flu season? What consideration has he given to expanding Pharmacy First to establish a community pharmacist prescribing service covering a broader range of common conditions?
The Minister will know that in some countries, which are way ahead of the Government on this, such as Canada, pharmacists can prescribe for dozens of common conditions, freeing up millions of appointments in general practice every year. What is his long-term strategy to equip pharmacies for a future where their talents, capacity and expertise can be fully utilised and to fix the front door of the NHS?
Hon. Members have also raised a number of concerns about the financial pressures facing pharmacies. I know that the sector appreciates the additional funding announced in May, but that is of course tied directly to its expanded responsibilities as part of the primary care recovery announcement and does not recognise how current cost pressures are impacting the sector. Since the community pharmacy contractual framework was signed in 2019, the cost of doing business has continued to rise—especially since Elizabeth Truss crashed the economy.
The result has been many pharmacies closing their doors for good, disproportionately in the most deprived areas, as analysis from the Company Chemists’ Association has found. Last year alone, 110 pharmacies shut up shop, and many more have had to reduce opening hours, services and staffing. Will the Minister say what assessment he has made of the risk of more pharmacies closing down and reducing operations before the end of the current funding settlement in 2024 and what impact that will have on the NHS medicines supply, the knock-on pressures on other parts of primary care and the prospects for extended clinical services in the community setting?
As the Minister will know, the 2019 funding agreement was made on the promise that the Government would drive wider efficiency savings and regulatory changes across the system. For many community pharmacies, the roll-out of the hub-and-spoke model was an answer that would allow them to streamline their services. However, it has been 14 months since the Department of Health and Social Care’s consultation on hub-and-spoke dispensing closed, and we have still had no response from the Department, nor the secondary legislation that was promised. Can the Minister please give us answers today about the considerable delay in progressing with hub-and-spoke reform? What is the hold-up?
I would also like to raise the issue of staffing with the Minister. The community pharmacy workforce survey released last month revealed that, compared with 2021, there was a 6% reduction in the full-time equivalent workforce in 2022. The vacancy rate for pharmacy technicians was about 20%, whereas it was 16% for pharmacists and 9% for dispensing assistants. Two thirds of contractors said that they found it very difficult to fill pharmacist roles last year, and in turn, the bill for locum pharmacists rose by 80% last year alone. Many chemists are struggling to cope with those pressures, contributing to thousands of unplanned closures every month. That is bad for the taxpayer and bad for patients, so what assessment has the Minister made of the challenges faced by community pharmacies in hiring, training and retaining skilled pharmacy staff? Does he recognise that the Government’s workforce strategy has not kept pace with the scale of change in the sector? Does he share my concern that without a functioning community pharmacies network, the Government’s primary care recovery plan is built on very shaky foundations?
The next Labour Government have a plan to reform the NHS to shift care from acute settings to the community. As part of our plans to build a neighbourhood health service, we will realise the potential of community pharmacies, giving people services that they can rely on and access earlier on their doorstep. That will mean accelerating the roll-out of independent prescribing to establish a community pharmacist prescribing service that covers a broad range of common conditions. It will mean cutting unnecessary red tape to allow pharmacy technicians to step up, ensuring that pharmacists can work to the top of their licence and make more of their considerable expertise in prescribing and medicines management, rather than having repetitive dispensing processes. All of that will be supported by greater digital interoperability, allowing the profession to support GPs in the management of long-term conditions.
The Minister will have heard the broad support for the sector in today’s debate, as a trusted and cost-effective measure for addressing some of the chronic challenges we have come to expect under this Government. I look forward to his answers on what more he is doing to support this important sector and realise the potential of the pharmacy profession.
It is a pleasure to serve under your chairmanship, Sir Mark, and I congratulate my hon. Friend Peter Aldous on securing this important debate. I start by echoing his thanks to our hard-working pharmacists, who do such a brilliant job. He raised six main points in his speech, and I can confirm that we are working on all of them.
Community pharmacies play a crucial role in our health system and a greater role in looking after people’s health than ever before. Pharmacies are easily accessible, and about nine in 10 people who visit one are positive about the advice they receive. The Government are investing in pharmacy to do much more. The delivery plan for recovering access to primary care announced an investment of up to £645 million in a new Pharmacy First service—a whole new NHS service will be created—as well as an expansion of the existing blood pressure check and contraception services. Pharmacy First will enable patients to see a community pharmacist for seven common conditions and be supplied with prescription-only medicines without the need for a GP. We are consulting Community Pharmacy England on the proposals in that delivery plan, with the aim of starting Pharmacy First this winter.
Pharmacy First builds on the community pharmacy contractual framework 2019 to 2024 five-year deal. That deal commits £2.592 billion a year to the sector and sets out how community pharmacy will be more integrated into the NHS, delivering more clinical services and effectively becoming the first port of call for minor illness. Under that deal, we have introduced minor illness referrals from GPs to community pharmacies, which have been a great success. A&E and NHS 111 can also now refer patients for an urgent medicine supply without a prescription from their GP. More than 2.8 million consultations have been provided at community pharmacies for a minor illness or urgent medicine supply since the start of those services.
We also introduced blood pressure checks, and community pharmacies have delivered 1.4 million checks since October 2021 and more than 150,000 in May 2023 alone. Huge numbers of potentially life-saving checks are being done. NHS England estimates that in 2023, more than 1,300 heart attacks and strokes will be prevented thanks to those checks, so I repeat my thanks to this fantastic sector.
In April this year, we introduced an oral contraception service, making it easier for women to access contraception.
In addition, community pharmacies now support and advise more than a quarter of a million people a month when they start new medicines, through the new medicine service, and 10,000 patients every month who have had their medicines changed following a visit to hospital, through the discharge medicines service. That supports medicines adherence, prevents GP visits and hospitalisations, and gives people a much better sense that they are taking the right medicines.
Community pharmacies are also playing a growing role in our vaccination programmes. Last winter, they administered 29% of adult flu vaccinations and more than a third—36%—of covid-19 vaccinations.
We have talked about the funding issue. In addition to the £2.592 billion a year, we added an extra £50 million last and this financial year, and we have made the additional sum of money that I mentioned available for Pharmacy First and the expansion of existing services. On top of that, we pay separately for flu and covid vaccinations, which, as I suggested, provide an increasingly important income stream for pharmacies.
The current five-year deal is of course coming to an end, and we will need to consider what comes next for pharmacy. As part of that, NHS England has committed to commissioning an economic study to better understand the cost of delivering pharmaceutical services. That study will feed into any future funding decisions on community pharmacy.
Several hon. Members raised the issue of the number of pharmacies, and we monitor that very closely. Our data shows that despite a number of pharmacies closing since 2017, there are about 10,800 pharmacies today, which is still more than in 2010. Despite the things that have happened to other high street businesses, we still see that there are more pharmacies and there are an awful lot more pharmacists—I will come on to that when we talk about the workforce.
However, rather than focusing merely on numbers, we should look at access. We know that 80% of the population live within 20 minutes’ walk of a pharmacy, and that there are twice as many pharmacies in more deprived areas. Sir George Howarth is right that they play a crucial role in providing access in deprived areas. We ensure that that continues to be the case. Proportionally, the closures that we have seen reflect the spread of pharmacies across England.
We are seeing changes in the market, with some of the large pharmacy businesses divesting. That has an impact on the make-up of the sector: we are seeing the number of small independent pharmacies increase, while the number of pharmacies that are part of bigger businesses decrease. We are monitoring the market very closely as it evolves.
As my hon. Friend the Member for Waveney mentions, through the pharmacy access scheme, we are financially supporting pharmacies in areas where there are fewer pharmacies and where there might be a challenge in getting access. To address the disproportionately high rate of closures of pharmacies that must be open for a minimum of 100 hours—the so-called 100-hour pharmacies —legislation was amended in April to allow those pharmacies to reduce their hours to a minimum of 72, which is still a huge number of hours to be open. That will support those pharmacies to remain open, providing extended hours, particularly for weekend access.
The same legislation gave integrated care boards the possibility of introducing local hours plans. That enables the local co-ordination that will ensure that there is something available locally at all times when people need it. It allows temporary closures in an area if there are significant difficulties with access and ensures that a pharmacy is always open somewhere in an area.
Some pharmacies struggle to find staff, and in some instances they have had to close temporarily, because a pharmacy cannot open without a pharmacist. There is more demand than ever for pharmacy professionals—an issue raised by various hon. Members, including Judith Cummins and my right hon. Friend Esther McVey. Since 2010, the number of registered pharmacists in England has increased by 82%, from 28,984 to 52,780. That means nearly 24,000 more pharmacists registered in England this year than in 2010. It is a huge increase, even compared with the huge increases elsewhere in the NHS.
On top of that, we have published the “NHS Long Term Workforce Plan”, backed by more than £2.4 billion to fund further additional increases and more training places over the next five years. The plan sets out the steps that the NHS and education providers will take to deliver an NHS workforce who meet the changing and growing needs of the population over the next 15 years. Our ambition is to increase training places for pharmacists by nearly 50%—building even further on what we have already done—to around 5,000 by 2031-32, and to grow the number of pharmacy technicians.
Employers clearly have a key role in retaining staff and making jobs in community pharmacy attractive. To support employers, we are investing in training to help private contractors to deliver high-quality NHS services. NHS England has provided a number of fully funded training opportunities for pharmacists and pharmacy technicians—Taiwo Owatemi raised an interesting and important point on this matter. That is why we are providing 3,000 independent prescribing training places—applications for this year are now available to pharmacists—and, on top of that, another 1,000 fully funded training places for designated prescribing practitioners, or DPPs. As well as growing the number of people entering the workforce, we are making provisions to upskill those who are already in the workforce. We are as just excited as other hon. Members present about the huge potential of independent prescribing in pharmacy to build even more on what we are doing to grow the range of services in community pharmacies.
I have talked about what we are doing on funding and the workforce, but I also want to talk about structural reform and efficiencies, and enabling pharmacists to do more with the skills they have—an important point raised by a number of hon. Members. The plan for primary care sets out some of the things we are doing, including modernising legislation to make it clear that pharmacists no longer have to directly supervise all the activities of pharmacy technicians, who are, in fact, registered health professionals in their own right.
Hon. Members are right to point out that the nature of work in pharmacy has changed, and we must change the legislation to match that. We also plan to enable any member of the pharmacy team to hand out appropriately checked and bagged medicines in the absence of a pharmacist, remedying frustrating instances where patients are delayed, having to wait perhaps because the pharmacist has popped out for lunch. We are also consulting on changes to the legislation to enable pharmacy technicians to use patient group directions, which would enable pharmacy technicians to do more.
Last week, the House debated legislation to give pharmacists the flexibility to dispense medicines in their original packs, so that pharmacists use their high-end clinical skills rather than spending time snipping out blister packs, which is not a good use of their time. We are progressing legislation to enable hub-and-spoke dispensing—the Chair of the Health and Social Care Committee, my hon. Friend Steve Brine, rightly mentioned that—following public consultation on the changes.
Finally, we are also working with medicine suppliers to identify medicines that could be reclassified from being available only on prescription, known as “POM”, to being available in a pharmacy, known as “P”.
This is a huge package of structural reforms and a huge liberalisation of the structure of pharmacy, enabling pharmacists with ever-growing clinical skills to do more and not be caught up in bureaucracy.
The Government are thinking beyond that about what pharmacy can do in the longer term. Hon. Members are right that Pharmacy First, the fantastic new NHS service, could be added to over time. NHS England is also starting independent prescribing pilots, with a view to implementing pharmacy prescribing services in the future, based on what we learn from them. That has huge potential to take further pressure off GPs and make the best possible use of all the new skills in the pharmacy workforce.
The Chair of the Health and Social Care Committee, my hon. Friend the Member for Winchester, raised an important point about access to PrEP, as an example of an advanced service that pharmacies could provide. As he will know, partly because of his work in initiating this, the PrEP access and equity task and finish group was established in 2022 as a sub-group of the HIV action plan implementation steering group, to improve access to PrEP. That steering group is working to develop a PrEP road map based on the task and finish group’s recommendations. I can say today that the road map will be out before the end of the year, and it will deal with how we will work through all the knotty issues in enabling community pharmacy to provide PrEP.
I thank my hon. Friend the Member for Waveney for raising these hugely important issues, which are crucial to community pharmacy. The sector is doing more than ever before, seeing more people, providing a wider range of services and becoming more clinically advanced than ever. There are pressures in the sector, but we are injecting further funding. We have grown the workforce hugely. We will continue to build on what community pharmacists do to further improve community pharmacy across the country.
This has been a very informative and helpful debate. We clearly have an enormous challenge in this country in improving access to primary care, and the key role played by the community pharmacy in addressing that challenge will be vital. We have heard about the three shortages that the industry faces, and I urge the Minister to reflect on those: the shortage of funding and finance, the shortage of staff, and the shortage of medicines.
Sir George Howarth highlighted the impact of community pharmacy closures on deprived areas. It is clear from the maps that have been produced that the impact is disproportionate, including in some coastal communities, such as the one I represent. He also highlighted the key role that community pharmacies play in treating the long-term health conditions found in such areas.
My hon. Friend Steve Brine, the Chair of the Health and Social Care Committee, rightly showed that this issue is on its register. I looked at the registers in the Select Committee report and I look forward to the amber and red warnings turning into green notices in due course. He highlighted the importance of PrEP being available for community pharmacies—the Terrence Higgins Trust brought that to my attention—and I welcome the update that the Minister provided.
Judith Cummins clearly emphasised the importance of a prevention-first approach. We got the first-hand knowledge that is so important in forums such as this from Taiwo Owatemi. I was particularly struck by her emphasis on the importance of using technology and the specific problem with the manufacture of generic medicines—she made her point very well. The shadow Minister, Preet Kaur Gill, reinforced the potential of the sector and what an alternative Labour Administration would do.
The Minister highlighted the whole range of work that community pharmacies can do. He touched on the closures but said that there are actually more community pharmacists now than in 2010. I just highlight, from talking to community pharmacists, that when there are closures, getting consolidation of the sector across the country, so there is an even spread and we retain community pharmacies within 20 minutes of people, is not straight- forward with the current regulations. I urge the Minister and his Department to look at that.
The Minister also said there has been an 82% increase in registered pharmacists since 2010, but a lot of that increase may have been in hospitals and medical practices. The feedback that I get from community pharmacists is that they have challenges with recruitment and retention in their settings, and we need to address that. I was heartened by what the Minister said about regulatory reform; it appears that the Government are embracing that particular challenge.
Let me say, in the few seconds I have left, that this debate has served the purpose of highlighting the key role of community pharmacies and the challenges they face. I urge the Minister to continue to engage with the sector—I know he will—particularly when the extra report is produced on Tuesday.
Question put and agreed to.
That this House
has considered community pharmacies.